Down 20% in 14 weeks, is AstraZeneca’s share price now too big a bargain for me to miss?

AstraZeneca’s share price has fallen a long way on an investigation surrounding its Chinese business. So, do the shares look unmissably cheap to me now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Person holding magnifying glass over important document, reading the small print

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

On 13 August, AstraZeneca’s (LSE: AZN) share price had risen so much that the firm became the UK’s first listing with a market capitalisation of £200bn. And on 3 September, the pharmaceutical giant hit a 12-month traded high of £133.38.

Just 14 weeks on, the share price has dropped 20%.

As a former investment bank trader, I have long known how fickle the markets can be. As a private investor nowadays, I know that they can provide extraordinary buying opportunities.

Should you invest £1,000 in Diageo right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Diageo made the list?

See the 6 stocks

So, is AstraZeneca one of these right now?

Why have the shares tumbled?

The key reason behind the fall were rumours, later confirmed, that Chinese authorities are investigating AstraZeneca’s operations in the country.

The firm recently stated that the investigations include allegations of medical insurance fraud, illegal drug importation and personal information breaches.

In H1 2024, 13% of the company’s revenue came from China – totalling $3.378bn (£2.66bn). So any outcome of China’s investigations that threaten its income is a significant risk for the firm. Another risk for it is any failure in one of its core products that would be very costly to fix.

However, its Chinese operations are ongoing under the firm’s national general manager. And its long-term financial forecasts remain in place.

Recent results and long-term projections

Indeed, in its nine-month and Q3 results released on 12 November it increased key guidance, for this year at least.

Total revenue is now expected to increase by a high-teens percentage (from the mid-teens previously). And core earnings per share (EPS) are also now forecast to rise by a high-teens percentage (from the mid-teens).

These guidance upgrades came on the back of a 19% year-on-year increase over the nine months – to $39.182bn (£30.74bn). Core EPS jumped 11% to $6.12.

Longer term, AstraZeneca still forecasts $80bn+ in revenues by 2030, against $45.8bn at the end of 2023.

Consensus analysts’ estimates are that its earnings will grow 18.2% a year to the end of 2026.

How does the share valuation look?

On the price-to-earnings key stock valuation measure, AstraZeneca trades at 31.8. This is bottom of its competitor group, which averages 56.7. So, it looks a major bargain on this basis.

The same is true for its price-to-book valuation of just 5.1 against a competitor average of 34.8.

And it is also the case with its bottom-ranked price-to-sales valuation of only 4 compared to its peers’ average of 11.9.

To put these into the context of share price, I ran a discounted cash flow (DCF) analysis. This shows the stock is 53% undervalued at its current price of £106.80.

Therefore, the fair value for the shares is £227.23, although they may trade lower or higher than that.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL10 Dec 201910 Dec 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

Will I buy the stock?

I bought AstraZeneca shares several times in the past few years at various prices, so I have a good position. That said, the price now compared to where I think it will be in a few years is too tempting for me to miss.

I do not expect significant damage to the firm’s China business to result from the ongoing investigations. But even if there is, I think AstraZeneca is more than able to compensate through growth elsewhere over time.

So, I will be adding to my holding very soon.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Pound coins for sale — 51 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

artificial intelligence investing algorithms
Investing Articles

Up 272% in just a year, is Palantir stock just getting started?

This writer recognises that Palantir has grown its business very well -- but does the stock price offer him an…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Up 50%? The Aston Martin share price forecast is mind-blowing! 

If analysts are right, the Aston Aston Martin share price could absolutely rocket in the year ahead. Harvey Jones says…

Read more »

Investing Articles

As the S&P 500 drops, here are 2 Stocks and Shares ISA holdings I’m watching

Our writer has different views on how President Trump's tariffs might affect these two US holdings in his Stocks and…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

£10,000 invested in Tesla stock at Christmas is now worth…

Tesla stock has been one of best-performing investments of the past decade. But things haven't gone to plan for investors…

Read more »

Investing Articles

Up 279% in 5 years, could Meta stock keep soaring?

Meta stock has more than tripled in five years. This writer sees lots to like about the business but also…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

25% total return in a year? Is now the perfect time to buy BP shares?

BP shares are on the front line of today's global economic and political uncertainty but analysts think they can still…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

With Cash ISA changes coming, could now be the time to consider buying shares?

Changes to the Cash ISA could lead to greater investment in the stock market. This could be a good thing…

Read more »

Investing Articles

These FTSE 100 dividend shares just got cheaper, thanks to President Trump!

Investors buying dividend shares can lock in bigger long-term yields when share prices take a tumble. These two just did…

Read more »